Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamate dehydrogenase 1 pseudogene 2 (GLUD1P2) is a pseudogene, meaning it is a genomic element that resembles the protein-coding gene glutamate dehydrogenase 1 (GLUD1) but contains disabling mutations preventing it from encoding a functional protein[2][4][6][8]. While pseudogenes were once considered nonfunctional "dead" genes, modern studies show some can produce RNA transcripts that influence gene regulation, often through RNA-mediated interactions. However, there is currently no evidence for a direct functional, regulatory, or disease-associated role unique to GLUD1P2. These pseudogenes are not considered therapeutic targets, and there are no drugs, biomarkers, or known mechanisms of drug action associated with GLUD1P2. In practice, GLUD1P2 is annotated for purposes of genome structure and evolution, rather than for its therapeutic potential[2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate dehydrogenase 1 pseudogene 2 (GLUD1P2).